Providence Therapeutics begins first clinical trials of Canadian-made COVID-19 vaccine

CALGARY — Human clinical trials have begun in Toronto for a proposed COVID-19 vaccine by a Canadian company.

Providence Therapeutics of Calgary says 60 subjects will be monitored for 13 months, with the first results expected next month.

A group of healthy volunteers aged 18 to 65 have been divided into four groups of 15. Each of the three group is receiving three different dose levels, while a fourth group gets a placebo.

Pending regulatory approval, the company’s CEO Brad Sorenson says a larger Phase 2 trial may follow in May with seniors, younger subjects and pregnant people.

Providence uses messenger R-N-A technology for a product it calls P-T-X COVID-19 B.

Sorenson says if successful, the vaccine could be released by the end of the year.

This report by The Canadian Press was first published Jan. 26, 2021.

View original article here Source

Related Posts